ReviewBiomarkers in medicine2015
Translational metabolomics in cancer research.
Review in Biomarkers in medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Rapid discrimination of human oesophageal squamous cell carcinoma by mass spectrometry based on differences in amino acid metabolism.Scientific reports · 2017Trial
- Role of untargeted omics biomarkers of exposure and effect for tobacco research.Addiction neuroscience · 2023Article
- Challenges in Metabolomics-Based Tests, Biomarkers Revealed by Metabolomic Analysis, and the Promise of the Application of Metabolomics in Precision Medicine.International journal of molecular sciences · 2022Review
- Presence of human breast cancer xenograft changes the diurnal profile of amino acids in mice.Scientific reports · 2022Article
- Global Trend in Research and Development of CDK4/6 Inhibitors for Clinical Cancer Therapy: A Bibliometric Analysis.Journal of Cancer · 2021Article
- Reliable identification of prostate cancer using mass spectrometry metabolomic imaging in needle core biopsies.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- Translational Metabolomics: Current Challenges and Future Opportunities.Metabolites · 2019Article
- A Review of Pulmonary Toxicity of Electronic Cigarettes in the Context of Smoking: A Focus on Inflammation.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Review
- Company profile: BluePen Biomarkers LLC – integrated biomarker solutions.Future science OA · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Over the last decade there has been a bottleneck in the introduction of new validated cancer metabolic biomarkers into clinical practice. Unfortunately, there are no biomarkers with adequate sensitivity for the early detection of cancer, and there remain a reliance on cancer antigens for monitoring treatment. The need for new diagnostics has led to the exploration of untargeted metabolomics for discovery of early biomarkers of specific cancers and targeted metabolomics to elucidate mechanistic aspects of tumor progression. The successful translation of such strategies to the treatment of cancer would allow earlier intervention to improve survival. We have reviewed the methodology that is being used to achieve these goals together with recent advances in implementing translational metabolomics in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.